1) Kivisto KT : A review of assay methods for cyclosporin. Clinical implications. Clin Pharmacokinet 23 : 173-190, 1992
2) Peters DH et al : Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 46 : 746-794, 1993
3) Kolars JC et al : First-pass metabolism of cyclosporin by the gut. Lancet 338 : 1488-1490, 1991
4) Hooks MA : Tacrolimus, a new immunosuppressant-a review of the literature. Ann Pharmacother 28 : 501-511, 1994
5) Mancinelli LM et al : The pharmacokinetics and metabolic disposition of tacrolimus : a comparison across ethnic groups. Clin Pharmacol Ther 69 : 24-31, 2001
6) Bekersky I et al : Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. J Clin Pharmacol 41 : 289-297, 2001
7) Wiernik PH et al : Cyclophosphamide in human milk. Lancet 1 : 912, 1971
8) Boumpas DT et al : Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340 : 741-745, 1992
9) Haubitz M et al : Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement : a prospective, randomized study. Arthritis Rheum 41 : 1835-1844, 1998
10) Guillevin L et al : A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 40 : 2187-2198, 1997
11) Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet 344 : 423-428, 1994
12) The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 331 : 1110-1115, 1994
13) Schwartz RB et al : Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy : CT and MR findings in 16 cases. AJR Am J Roentgenol 165 : 627-631, 1995
14) Hinchey J et al : A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334 : 494-500, 1996
15) Eidelman BH et al : Neurologic complications of FK 506. Transplant Proc 23 : 3175-3178, 1991
16) Wijdicks EF et al : Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression. Neurology 45 : 1962-1964, 1995
17) Weir MR et al : Risk for posttransplant Diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 34 : 1-13, 1999
18) Olshan AF et al : International Commission for Protection Against Environmental Mutagens and Carcinogens. Cyclosporine A : review of genotoxicity and potential for adverse human reproductive and developmental effects. Report of a Working Group on the genotoxicity of cyclosporine A, August 18, 1993. Mutat Res 317 : 163-173, 1994
19) Cockburn I et al : Present experience of Sandimmun in pregnancy. Transplant Proc 21 : 3730-3732, 1989
20) Masala A et al : Use of testosterone to prevent cyclophosphamide-induced azoospermia. Ann Intern Med 126 : 292-295, 1997
21) Somers EC et al : Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 52 : 2761-2767, 2005
22) Balow JE et al : NIH conference. Lupus nephritis. Ann Intern Med 106 : 79-94, 1987
23) Regan MJ et al : Treatment of Wegener's granulomatosis. Rheum Dis Clin North Am 27 : 863-886, viii. 2001